Galderma Offers Strong Growth Profile -- Market Talk
Dow Jones2026/10/28 10:511051 GMT - Galderma should continue to experience strong top-line growth next year, J.P. Morgan analysts write in a research note. The Swiss dermatology company should continue to benefit from sales of its Nemluvio drug, as well as from the acquisition of ZO Skin Health, the analysts say. "Overall, we continue to view Galderma as offering one of the strongest growth profiles in European mid-cap pharma," they add. JPM maintains its overweight rating on the stock. Shares are up 0.6%. (andrea.figueras@wsj.com)
(END) Dow Jones Newswires
October 28, 2026 06:51 ET (10:51 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
